Myelomide (Lenalidomide)

Lenalidomide (Myelomide) is used in hematologic malignancies that involve abnormal plasma or lymphoid cells.

• Multiple myeloma: improves progression‑free survival and overall response rates in eligible adult patients.
• Myelodysplastic syndromes: reduces transfusion dependence and delays progression to acute leukemia.
• Mantle cell lymphoma: enhances overall response when combined with standard chemotherapy regimens.

• Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, altering substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, resulting in modulation of cytokine production, enhanced T‑cell and NK‑cell activity, and inhibition of angiogenesis, collectively producing anti‑tumor effects.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require fluid replacement.
• Nausea: mild to moderate upset stomach.
• Rash: skin irritation or redness.
• Peripheral neuropathy: tingling or numbness in extremities.
• Constipation: difficulty passing stools.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe neutropenia: markedly reduced neutrophil count increasing infection risk.
• Anemia: significant drop in red blood cells causing weakness.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Secondary malignancies: rare occurrence of new cancers.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should evaluate patient history and monitor laboratory parameters.

• Pregnancy risk: contraindicated in pregnancy due to teratogenicity; ensure effective contraception.
• Thrombosis risk: assess for clotting disorders and consider prophylactic anticoagulation.
• Renal function: adjust monitoring for patients with impaired kidney function.
• Hepatic function: monitor liver enzymes regularly.
• Blood counts: perform baseline and periodic complete blood counts.
• Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and light.

Lenalidomide may interact with several concomitant medications, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: may reduce drug exposure (e.g., rifampin).
• Anticoagulants: increased risk of bleeding when combined with warfarin or DOACs.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors: may increase plasma levels (e.g., ketoconazole).
• Immunosuppressants: heightened infection risk when used with corticosteroids.
• Vaccines: live vaccines should be avoided during treatment.